Loading
CIITA (MHC class II transactivator) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Head and neck squamous cell carcinoma, Skin cancer, Colorectal cancer and 4 more. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 2 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Essential for transcriptional activity of the HLA class II promoter; activation is via the proximal promoter. Does not bind DNA. May act in a coactivator-like fashion through protein-protein interactions by contacting factors binding to the proximal MHC class II promoter, to elements of the transcription machinery, or both PubMed:8402893, PubMed:7749984,. Alternatively it may activate HLA class II transcription by modifying proteins that bind to the MHC class II promoter. Also mediates enhanced MHC class I transcription; the promoter element requirements for CIITA-mediated transcription are distinct from those of constitutive MHC class I transcription, and CIITA can functionally replace TAF1 at these genes. Activates CD74 transcription. Location: Nucleus; Nucleus, PML body (UniProt). Locus 16p13.13 (HGNC).
No product in the corpus is aimed at this target yet.
No trial in the corpus names this target or one of its products.
Hodgkin lymphoma responds despite deficient MHC class I. Across the CheckMate 205 biopsies, class I and beta-2-microglobulin did not predict complete remission but class II did, which points at a CD4 T cell as the effector and makes class II loss the escape route.
Fusions of the master transactivator of MHC class II lower class II on the tumour cell and in the same event place the PD-1 ligands under new promoters, so one rearrangement both hides the tumour and raises the brake.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"CIITA" OR ABSTRACT:"CIITA" OR TITLE:"class II major histocompatibility complex transactivator" OR ABSTRACT:"class II major histocompatibility complex transactivator" OR TITLE:"MHC class II transactivator" OR ABSTRACT:"MHC class II transactivator" OR TITLE:"C2TA" OR ABSTRACT:"C2TA" OR TITLE:"MHC2TA" OR ABSTRACT:"MHC2TA") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CIITA, not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/ciita.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/ciita.json. Licence CC BY-NC 4.0.